Glucotrack and Lōkahi Therapeutics Complete Strategic Business Combination, Establishing Lōkahi-Controlled Public Platform
Rhea-AI Summary
Glucotrack (Nasdaq: GCTK) has completed its strategic business combination with Lōkahi Therapeutics, creating a publicly listed platform focused on identifying, acquiring, and advancing differentiated healthcare assets. The structure makes Lōkahi the operating and controlling business, using Glucotrack’s public listing to support long-term growth and capital access.
Lōkahi’s late-stage clinical program and ai²-driven asset sourcing platform are being integrated with Glucotrack’s technology infrastructure. Lōkahi securityholders received Glucotrack common and convertible preferred stock that, after stockholder approvals and Nasdaq requirements, is expected to convert into common equity, giving them about 90% of the combined company on a fully diluted basis. A planned private placement is intended to bolster capital, while Glucotrack’s continuous blood glucose monitoring business will continue as a wholly owned subsidiary. Erik Emerson becomes CEO of the combined company, with Paul Goode as CTO and CEO of the CBGM subsidiary.
Positive
- Business combination completed, establishing Lōkahi as the controlling operating business
- Lōkahi securityholders expected to own about 90% of the combined company on a fully diluted basis
- Planned private placement financing to strengthen the combined company’s capital position
- CBGM business retained in a wholly owned subsidiary with dedicated operating structure
- Unified leadership named: Erik Emerson as CEO and Paul Goode as CTO
Negative
- Existing Glucotrack shareholders reduced to about 10% ownership on a fully diluted basis after conversion
- Conversion of preferred stock contingent on stockholder approvals and Nasdaq listing requirements, adding execution uncertainty
News Market Reaction – GCTK
In the Jul 15 session, GCTK declined 0.02%, reflecting a mild negative market reaction. Argus tracked a peak move of +124.6% during that session. Our momentum scanner triggered 117 alerts that day, indicating very high trading interest and price volatility. Trading volume was exceptionally heavy at 34.4x the daily average, suggesting significant selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 08 | Patent allowance | Positive | +1.7% | USPTO Notice of Allowance expanding protection for CBGM implantable platform. |
| May 26 | Conference showcase | Positive | +18.9% | Planned ADA 2026 presentation highlighting implantable CBGM technology and new data. |
| May 14 | 1Q26 earnings | Positive | -3.0% | Quarterly results with narrower net loss and CBGM program progress. |
| May 07 | IDE submission | Positive | +0.8% | FDA IDE submission for U.S. clinical study of implantable CBGM system. |
| Apr 30 | Clinical data | Positive | -7.3% | Peer-reviewed study showing long-term accuracy and stability of CBGM technology. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent Glucotrack news has produced mixed reactions, with several positive CBGM developments seeing both double-digit gains and notable declines.
Key Terms
convertible preferred stock financial
private placement financing financial
nasdaq listing requirements regulatory
subsidiary technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Transaction positions the combined company to execute a capital-efficient, repeatable strategy leveraging public market access and Lōkahi Therapeutics ai²-driven asset sourcing, development, and advancement platform
RUTHERFORD, N.J. and LA JOLLA, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) today announced the completion of its strategic business combination with Lōkahi Therapeutics, establishing a publicly listed, capital-efficient platform for the identification, acquisition, and advancement of differentiated healthcare assets.
The transaction is structured such that Lōkahi Therapeutics becomes the operating and controlling business of the combined company, leveraging Glucotrack’s public market platform to support long-term growth and access to capital. The combined organization integrates Lōkahi Therapeutics’ dual-engine model - its late-stage clinical development program and ai²-driven asset sourcing and advancement platform - with Glucotrack’s existing technology infrastructure to create a scalable, repeatable framework for value creation.
In connection with the closing, Lōkahi Therapeutics securityholders received a combination of Glucotrack common stock and convertible preferred stock. Upon receipt of required stockholder approvals and satisfaction of applicable Nasdaq listing requirements, the preferred stock is expected to convert into common equity, resulting in Lōkahi Therapeutics securityholders holding approximately
The transaction is supported by a planned private placement financing designed to strengthen the combined company’s capital position and support near-term execution. A designated portion of the proceeds is expected to be allocated to support the continued development and operation of Glucotrack’s legacy continuous blood glucose monitoring (CBGM) technology within a dedicated subsidiary structure.
Glucotrack’s CBGM business will operate as a wholly owned subsidiary of the combined company, with its operations, assets, and capital structure maintained separately to enable focused execution and strategic flexibility.
Erik Emerson has been appointed Chief Executive Officer of the combined company, providing unified leadership across the organization. Paul Goode will serve as Chief Technical Officer of the combined company and Chief Executive Officer of the CBGM subsidiary.
“This transaction establishes a capital-efficient, publicly listed platform designed to systematically identify, acquire, and advance differentiated healthcare assets,” said Erik Emerson, Chief Executive Officer. “By combining public market access with Lōkahi Therapeutics’ ai² platform and disciplined operating model, we are positioned to expand our pipeline, strengthen our capital structure, and pursue a broader set of strategic opportunities.”
Paul Goode, Chief Technical Officer, added: “This combination enables the continued advancement of Glucotrack’s core technology within a focused operating structure while participating in a broader platform designed for scalable growth. We believe this integrated approach supports disciplined execution across both operating priorities.”
About Lōkahi Therapeutics
Lōkahi Therapeutics is a capital-efficient biopharmaceutical platform company focused on identifying, evaluating, acquiring, and advancing overlooked therapeutic assets. Through its ai² platform and ai² Futures Lab execution model, Lōkahi integrates cross-functional expertise and disciplined decision-making to drive strategic development and long-term value creation. For more information, visit www.lokahithera.com.
About Glucotrack, Inc.
Glucotrack, Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes, including a long-term implantable continuous blood glucose monitoring system. The Glucotrack CBGM is an Investigational Device and is limited by federal (or United States) law to investigational use. For more information, please visit www.glucotrack.com.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "anticipate", "believe", "expect", "plan," and "will" are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, management. These statements relate only to events as of the date on which the statements are made, and Glucotrack undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. All of the forward-looking statements made in this press release are qualified by these cautionary statements, and there can be no assurance that the actual results anticipated by Glucotrack will be realized or, even if substantially realized, that they will have the expected consequences to or effects on us or our business or operations. Readers are cautioned that certain important factors may affect Glucotrack's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Glucotrack's results include, but are not limited to, the ability of Glucotrack to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to merger integration; risks relating to the receipt (and timing) of regulatory approvals (including U.S. Food and Drug Administration approval); risks relating to enrollment of patients in, and the conduct of, clinical trials; risks relating to Glucotrack's future distribution agreements; risks relating to its ability to hire and retain qualified personnel, including sales and distribution personnel; and the additional risk factors described in Glucotrack's filings with the U.S. Securities and Exchange Commission (the "SEC"), including its Annual Report on Form 10-K for the year ended December 31, 2025 as filed with the SEC on March 30, 2026.
Media Contacts:
Glucotrack
GlucotrackPR@icrinc.com
Lōkahi Therapeutics
brian@lokahithera.com
